Radient Pharmaceuticals Corp (RPC), through its US-based subsidiary AMDL Diagnostics, will be presenting Onko-Sure in vitro diagnostic (IVD) Cancer Test at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Onko-Sure is a simple, non-invasive, patent-pending and regulatory-approved IVD test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer.
Onko-Sure had been approved by the FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test.
Douglas MacLellan, CEO of Radient Pharmaceuticals, said: “This is an extraordinary opportunity for RPC to present its USFDA approved Onko-Sure cancer diagnostic test to practicing oncologists from international countries across the globe.
“RPC’s goal is to communicate the important role Onko-Sure can play in the screening, detection, and monitoring of cancer for cancer patients. We continue to expand RPC’s presence in both the worldwide private and public healthcare markets, addressing the growing cancer challenge.”